Hyperlipidaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:21:31 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperlipidaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Enlicitide and Rosuvastatin for Adults With High Cholesterol https://clinicaltrials.eu/trial/a-study-of-enlicitide-and-rosuvastatin-for-adults-with-high-cholesterol/ Wed, 29 Apr 2026 15:07:55 +0000 https://clinicaltrials.eu/trial/a-study-of-enlicitide-and-rosuvastatin-for-adults-with-high-cholesterol/ This study involves people with hyperlipidemia, which is a condition where there are high levels of fats, including cholesterol, in the blood. The study will test a medication called MK-0616, which contains the active substance enlicitide chloride, given together with another medication called rosuvastatin. Rosuvastatin is a medicine that helps lower cholesterol levels and is already used in medical practice. Some participants will receive the actual medications while others will receive placebo, which is an inactive treatment that looks like the real medication but contains no active medicine.

The purpose of the study is to compare how well enlicitide combined with rosuvastatin works compared to placebo in lowering cholesterol levels, specifically a type of cholesterol called low-density lipoprotein cholesterol, in the blood after eight weeks of treatment. The study will also look at the safety of this combination of medications by monitoring any unwanted effects that may occur during the treatment period.

Participants in this study will take the study medications by mouth in the form of film-coated tablets for up to twelve months. During the study, measurements will be taken at different time points, particularly at week eight and week twelve, to see how the cholesterol levels change from the beginning of the study. The study will also measure other types of fats in the blood and count how many participants reach certain target cholesterol levels. The study is expected to start enrolling participants in late 2025 and continue until early 2027.

]]> Study on the Effects of Alirocumab and Drug Combination on Hyperlipidemia in Patients https://clinicaltrials.eu/trial/study-on-the-effects-of-alirocumab-and-drug-combination-on-hyperlipidemia-in-patients/ Wed, 29 Apr 2026 15:02:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-alirocumab-and-drug-combination-on-hyperlipidemia-in-patients/ This clinical trial is focused on studying the effects of cholesterol-lowering drugs on various aspects of health, including their relationship with steroid hormones, bile acids, muscle morphology (the structure of muscles), vitamin D, the immune system, and related conditions such as depression and osteoporosis. The main goal is to determine if these medications can reduce the levels of steroid hormones in the body. The diseases being studied include hyperlipidemia, which is a condition characterized by high levels of lipids (fats) in the blood.

The trial involves several cholesterol-lowering medications, including alirocumab, rosuvastatin, evolocumab, atorvastatin, and inclisiran. These medications are used to help manage cholesterol levels and are administered in different forms, such as tablets or injections. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Participants in the study will be monitored over a period of up to 36 months. During this time, they will receive one of the cholesterol-lowering medications or a placebo. The study will observe changes in the levels of sex steroids, which are hormones that play a role in sexual development and reproduction. The trial aims to provide valuable insights into how these medications might affect various bodily functions and conditions related to cholesterol management.

]]> Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ This clinical trial is focused on studying the effects of treatments for hyperlipidemia, a condition characterized by high levels of fats, such as cholesterol, in the blood. The study will use medications containing rosuvastatin and a combination of rosuvastatin and ezetimibe. These medications are designed to help lower levels of low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol, in patients who are at high or very high risk of cardiovascular disease.

The purpose of the study is to evaluate how effective and safe these treatments are in achieving specific cholesterol level goals over a period of 12 weeks. Participants will be divided into different groups, with some receiving rosuvastatin alone and others receiving the combination of rosuvastatin and ezetimibe. The study will monitor changes in cholesterol levels at different intervals, specifically after 4, 8, and 12 weeks of treatment.

Throughout the study, participants will take the medications orally in the form of film-coated tablets. The trial aims to determine the proportion of patients who reach their LDL-C goals, which are set based on their risk levels for cardiovascular disease. The study will also assess the overall changes in cholesterol and other related blood fats to understand the effectiveness of the treatments. Participants’ adherence to the treatment regimen will be monitored to ensure accurate results.

]]>